Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy.
Natural killer (NK) cells eradicate galectin-deficient malignant gliomas without the necessity for T cell cooperation. This phenomenon was discovered as a consequence of reducing glioma-derived galectin-1. We propose that stimulation of endogenous antitumor NK cell activity may be achieved by reducing potent tumor-derived NK cell inhibitors, such as galectin-1, and that such agents be tested in the clinic to treatbrain tumors.
Departments of Neurosurgery and Cell and Developmental Biology; and Immunology; Cancer Biology; and Neuroscience Training Programs; The University of Michigan Medical School ; Ann Arbor, MI, USA.
Pedro R
PR
Lowenstein
Departments of Neurosurgery and Cell and Developmental Biology; and Immunology; Cancer Biology; and Neuroscience Training Programs; The University of Michigan Medical School ; Ann Arbor, MI, USA.
Gregory J
GJ
Baker
Departments of Neurosurgery and Cell and Developmental Biology; and Immunology; Cancer Biology; and Neuroscience Training Programs; The University of Michigan Medical School ; Ann Arbor, MI, USA.
Maria G
MG
Castro
galectin-1; innate antitumor immunity; malignant glioma; natural killer cells